In this issue:
MRI evidence of acute inflammation in leukocortical lesions in early MS
Breastfeeding, ovulatory years, and risk of MS
Sodium intake and MS activity
Interpreting lymphocyte reconstitution data from trials of alemtuzumab
Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS
Quantifying risk of early relapse in CIS patients
Alemtuzumab improves QoL outcomesvs interferon beta-1a in active RRMS
Group exercise improves balance andreduces falls in MS patients
Comparing the efficacy of DMTs in MS
Association between MS, cancer risk,and immunosuppressant treatment
Please login below to download this issue (PDF)